Literature DB >> 8671570

Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease.

L von Hertzen1, R Isoaho, M Leinonen, R Koskinen, P Laippala, M Töyrylä, S L Kivelä, P Saikku.   

Abstract

BACKGROUND: The significance of persistent or recurrent respiratory infections in adult life for the development of chronic obstructive pulmonary disease (COPD) is still to a large extent unknown. A few clinical and experimental animal studies suggest that peripheral airways diseases may be due to the cumulative effects of recurrent respiratory infections over an extended period.
METHODS: C. pneumoniae-specific IgG and IgA antibody levels were determined in two elderly groups of male patients with COPD and in control subjects without the disease. The first group (N = 36) consisted of patients who were hospitalized due to an acute exacerbation of COPD. The second group of patients (N = 54) and the controls (N = 321) were participants in a community survey on respiratory diseases in the elderly. The criteria for seropositivity were defined as an IgG titre of >=16.
RESULTS: 89% of the hospitalized patients (group I) and 66% of the non-hospitalized patients (Group II) were IgA seropositive as compared to 55% of the controls. Derived from the logistic regression analysis, the odds ratio (OR) WAS 7.4 (95% CI : 2.1-25.7) between group I and the controls and 1.5 (0.7-2.9) between group II and controls. Furthermore, the difference in the age-adjusted geometric mean titres (GMT) of lgA antibodies between the group I and the controls was significant (53.0 for the patients versus 19.1 for the controls). On the contrary, no significant differences between the patients and the controls were found either in the proportion of IgG-seropositive or in the GMT of IgG antibodies. Two of the 29 patients with an exacerbation of COPD, for whom paired sera were available, showed an antibody response suggesting a current acute or reactivated chlamydial infection.
CONCLUSIONS: The results showed that C. pneumoniae lgA antibodies are found more frequently and in higher concentrations in COPD patients than in disease-free controls. The finding may indicate a chronic C. pneumoniae infection in these patients. The association persisted after controlling for the potential confounding effect of smoking.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671570     DOI: 10.1093/ije/25.3.658

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  9 in total

1.  Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases.

Authors:  N Teig; A Anders; C Schmidt; C Rieger; S Gatermann
Journal:  Thorax       Date:  2005-09-02       Impact factor: 9.139

2.  A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren.

Authors:  G Dal Molin; B Longo; T Not; A Poli; C Campello
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

3.  Atypical bacteria and macrolides in asthma.

Authors:  Paraskevi Xepapadaki; Ioanna Koutsoumpari; Vasiliki Papaevagelou; Christina Karagianni; Nikolaos G Papadopoulos
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

4.  Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in stable asthma and chronic obstructive pulmonary disease.

Authors:  Seoung-Ju Park; Yong-Chul Lee; Yang-Keun Rhee; Heung-Bum Lee
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

5.  Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment.

Authors:  F Blasi; S Damato; R Cosentini; P Tarsia; R Raccanelli; S Centanni; L Allegra
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

6.  Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study.

Authors:  Shigeo Muro; Yasuharu Tabara; Hisako Matsumoto; Kazuya Setoh; Takahisa Kawaguchi; Meiko Takahashi; Isao Ito; Yutaka Ito; Kimihiko Murase; Chikashi Terao; Shinji Kosugi; Ryo Yamada; Akihiro Sekine; Takeo Nakayama; Kazuo Chin; Michiaki Mishima; Fumihiko Matsuda
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

7.  Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysema.

Authors:  Eva Brandén; Judy Gnarpe; Gunnar Hillerdal; Lotta Orre; C Magnus Sköld; Magnus Löfdahl; Hirsh Koyi; Göran Tornling
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

8.  Smoking, season, and detection of Chlamydia pneumoniae DNA in clinically stable COPD patients.

Authors:  Marek Smieja; Richard Leigh; Astrid Petrich; Sylvia Chong; Dennis Kamada; Frederick E Hargreave; Charles H Goldsmith; Max Chernesky; James B Mahony
Journal:  BMC Infect Dis       Date:  2002-07-05       Impact factor: 3.090

9.  Evaluation and optimization of a commercial enzyme linked immunosorbent assay for detection of Chlamydophila pneumoniae IgA antibodies.

Authors:  Olfa Frikha-Gargouri; Radhouane Gdoura; Abir Znazen; Nozha Ben Arab; Jalel Gargouri; Mounir Ben Jemaa; Adnene Hammami
Journal:  BMC Infect Dis       Date:  2008-07-26       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.